TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02408289

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hi-Flav
Description: High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
Study: NCT03875157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: Intravenous infusion, C1D1 and afterwards Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI318
Description: Intravenous infusion Q3W
Study: NCT00409994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
Study: NCT06765577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Finger Blood Pressure Measurement
Description: Finger Blood Pressure Measurement were taken from three digits: the thumb (F1), the middle finger (F2), and the little finger (F3) from both arms.
Study: NCT02408289

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Epicatechin
Description: Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Procyanidins
Description: Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
Study: NCT04375254

Intervention type: OTHER
Intervention: NbB psychopharmacology training
Description: a two part course in psychopharmacology based on Neuroscience based Nomenclature
Study: NCT01689480

Intervention type: OTHER
Intervention: FSHD training
Description: The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
Study: NCT02611024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: lurbinectedin (PM01183) 4 mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: lurbinectedin (PM01183) 4 mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: lurbinectedin (PM01183) 4 mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 40 mg, 100 mg or 300 mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 40 mg, 100 mg or 300 mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 40 mg, 100 mg or 300 mg vials
Study: NCT02631928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human biphasic insulin
Description: investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human biphasic insulin, reference
Description: marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
Study: NCT03646214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Midline traction oral appliance
Description: Device positions the mandible forward to open airway; device can be titrated to gradually advance the mandible.
Study: NCT05674123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound
Description: Undergo rectal endoscopic ultrasound

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Chart Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Undergo resection with the Flex Robotic System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo resection with the Flex Robotic System
Study: NCT02693106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Visit corresponding to a standardize breakfast taken alone (control visit) followed by a period of 4-hour with multiple blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine
Description: Visit corresponding to a standardize breakfast with 5 g of leucine followed by a period of 4-hour with multiple blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate -
Description: Visit corresponding to a standardize breakfast with 3.6 g of butyrate followed by a period of 4-hour with multiple blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate +
Description: Visit corresponding to a standardize breakfast with 7.2 g of butyrate followed by a period of 4-hour with multiple blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Octanoate -
Description: Visit corresponding to a standardize breakfast with 5 g of octanoate followed by a period of 4-hour with multiple blood sampling.
Study: NCT03685578

Intervention type: DEVICE
Intervention: EmboTrap® Revascularization Device
Description: EmboTrap® Revascularization Device
Study: NCT02693106

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Octanoate +
Description: Visit corresponding to a standardize breakfast with 10 g of octanoate followed by a period of 4-hour with multiple blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnitine
Description: Visit corresponding to a standardize breakfast with 1.95 g of carnitine followed by a period of 4-hour with multiple blood sampling.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butter fraction
Description: Visit corresponding to a standardize breakfast with 65 g of butter fraction followed by a period of 4-hour with multiple blood sampling.
Study: NCT00160706

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol (CDP870)
Description: Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.~Up to 84 months of therapy in this study.
Study: NCT04231929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chemoembolization
Description: First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.~Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of BioPearl™ microspheres used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved.
Study: NCT02458768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVF-M HP Inj.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Menopur® Inj.
Study: NCT02796066

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Applied once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN2898
Description: Applied once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN2898
Description: Applied once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSN2898
Description: Applied once a day
Study: NCT03685578

Intervention type: DEVICE
Intervention: CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter
Description: CERENOVUS Large Bore Catheter/ EMBOVAC Aspiration Catheter

Intervention type: DEVICE
Intervention: CEREGLIDE 71 Intermediate Catheter
Description: CEREGLIDE 71 Intermediate Catheter
Study: NCT01960270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: INTERSTIM II
Description: A second stimulator is implanted on controlateral site

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: INTERSTIM II
Description: A second stimulator is implanted on controlateral site
Study: NCT03418584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HybridAPC
Description: HybridAPC is a device which combines submucosal fluid injection with APC
Study: NCT04582058

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Health of lifestyle
Description: Mobile health of lifestyle with an orientation about daily activities and necessary care to patients with CEID, and protocol of exercise training with images and guidelines to execute five days per week, with a duration of 50 minutes, and space for doubts which patients could send message to researcher.
Study: NCT00987870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFH772

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BFH772

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcipotriol/betamethasone
Study: NCT02537236

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acid supplementation with fish oil.
Study: NCT01115920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131 (Bendavia™)
Description: Single 4 hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131 (Bendavia™)
Description: Single 4 hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131 (Bendavia™)
Description: Single 4 hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131 (Bendavia™)
Description: Single 4 hour intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131 (Bendavia™)
Description: Single 4 hour intravenous infusion
Study: NCT00660933

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron sucrose
Description: Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl
Description: NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
Study: NCT00623740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
Study: NCT02717416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endo-Clot
Description: After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemoclip or electrical coagulation
Description: After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist. Electrical coagulation will be applied onto the bleeding lesions.
Study: NCT05937594

Intervention type: GENETIC
Intervention: Buccal swab saliva for further genetic testing
Description: Genetic testing. Whole saliva RNA will be isolated for downstream microRNA quantification.
Study: NCT04465461

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS) fissure completion
Description: Following Bronchoscopy and Chartis® balloon catheter assessment under general anaesthesia and confirmation of collateral ventilation, a unilateral VATS lobar fissure completion will be undertaken with buttressed staples and Coseal spray intended to eliminate collateral ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zephyr Valve insertion
Description: Following fissure completion surgery, subjects confirmed to be collateral ventilation negative will undergo bronchoscopic insertion of Zephyr® Valve(s) in the targeted lobe, under sedation or general anaesthesia.
Study: NCT04225598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038
Description: Patients will receive a 24 mg dose of injectable CAM2038 in the ED on Day 0.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine Sublingual Product
Description: COWS ≥ 8: Patients will receive 4mg of SL-BUP for a COWS score of 8-12 (mild withdrawal). After 30-45 minutes if tolerated and no unanticipated adverse reactions, an additional 4mg can be administered for a total of 8mg in the ED. Patients presenting with moderate-severe withdrawal (COWS \>≥ 13) will receive an initial dose of 8mg SL-BUP. All patients will receive a buprenorphine prescription and instructions for additional BUP doses to allow for up to a dose of 12mg if needed, and for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD (medications for opioid use disorder).~COWS 4-7: Patients will be provided with a uniform set of instructions to guide unobserved (home) induction. They will be prescribed doses of SL-BUP to allow them to take dose up to 12mg in the 24 hours after discharge. All patients will also receive a buprenorphine prescription for 16mg each subsequent day until their scheduled follow up appointment for ongoing MOUD.
Study: NCT05134337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Oral LOXO-305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Oral LOXO-305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Oral rifampin
Study: NCT02843802

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK Immunotherapy
Description: Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
Study: NCT02080182

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo acetylcysteine
Study: NCT05432908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Orofacial exercises and oropharyngeal functions
Description: Oropharyngeal exercises (derived from speech-language pathology) to the tongue and facial muscles exercises as well stomatognathic functions.
Study: NCT02775318

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stellate Ganglion Block
Description: Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: 10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcranial Doppler
Description: The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Digital Subtraction Angiography
Description: Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
Study: NCT00949884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan medoxomil
Description: Oral tablets, once daily, at either 20mg or 40mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: olmesartan medoxomil
Description: Oral tablets, once daily, at either 20mg or 40mg daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo oral tablets once daily for two weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: losartan potassium
Description: losartan potassium oral tablet at either 50mg or 100 mg daily dose.
Study: NCT03578614

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: 3 physical activity sessions are planned by week, 2 supervised and 1 non-supervised conducted over 6 months. On the first 2 months, the supervised sessions have 10 minutes of warm-up + 5 minutes active pause (balance, agility and coordinative exercises) + 15 minutes walking + 5 minutes active pause (resistance exercises - 1 series of 12 repetitions~- 3 callisthenic exercises) + 15 minutes walking + 5 minutes flexibility (1 series of 10 seconds in 3 different postures). The aimed intensity in these first two months is 12/13. Between the 2nd and the 4th months, the duration of the walking period increases, as well as the intensity, RPE 13/14. Between the 4th and the 6th months, again the duration of the walking period increases, as well as the intensity, RPE 14/15. To measure the intensity level of the physical activity, the Borg Rating of Perceived Exertion (RPE) ranging from 6 (rest) to 20 (maximum effort) is used.
Study: NCT02949921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant and 2% lidocaine HCL
Description: Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiesse injectable implant and 2% lidocaine HCL
Description: Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
Study: NCT01835262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine: 0.1 mg /kg given as IVP

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine:0.3 mg/given as IVP
Study: NCT02537236

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Omega-3 fatty acid supplementation with fish oil.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TLC nutritional intervention
Description: nutritional orientation.
Study: NCT04435171

Intervention type: PROCEDURE
Intervention: Renal transplantation
Description: Open or robot assisted renal transplantation

Intervention type: PROCEDURE
Intervention: Renal transplantation
Description: Open or robot assisted renal transplantation
Study: NCT02293395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: ASA 100 mg enteric-coated tablet once daily orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylsalicylic acid
Description: ASA 100 mg enteric-coated tablet once daily orally.
Study: NCT02537236

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.
Description: Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.
Description: Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
Study: NCT02293395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg tablet twice daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 2.5 mg tablet twice daily orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once daily orally.
Study: NCT02473588

Intervention type: DEVICE
Group type: OTHER
Intervention: Retia Medical Long Time Interval Analysis
Description: Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter
Study: NCT01444547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel and cisplatin
Description: Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.~14 days as a cycle, up to 8 cycles.
Study: NCT04686370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser treated implant surface
Description: Better marginal bone stability is expected for this type

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laser treated implant surface
Description: Better marginal bone stability is expected for this type
Study: NCT03845335

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant-supported restoration
Description: During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental implant-supported restoration
Description: During the oral surgery session for dental implant insertion, after implant site preparation, the opaque sealed envelope containing the patient allocation will be opened. Following the group allocation, the patient will receive either an HA-coated Hybrid or moderately rough dental implant